YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hippo signaling pathway, a kinase cascade that regulates many physiological processes such as organ size determination, cell proliferation, and tissue regeneration, has been shown to play a key role in resistance to KRAS inhibition [99].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [99]
Citations
Cites
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 236
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Research works printed but not linked: 1
- Piccolo, S., Panciera, T., Contessotto, P. & Cordenonsi, M. Nat. Cancer 4, 9–26 (2023).
Cited by
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 52
“Short-term adagrasib or sotorasib exposure induces the cytoplasmic relocalization of the E-cadherin and Scribble (Scrib) proteins and subsequent adaptive resistance to KRAS G12Ci [53,54].”
BackgroundSeale, T. S., Li, L., Bruner, J. K., Chou, M., Nguyen, B., Seo, J., Zhu, R., Levis, M. J., Pratilas, C. A., & Small, D. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13749 · Cited by 9
“The YAP/TAZ pathway is linked to AXL upregulation in cancer, and YAP has even been implicated as a driver of adaptive resistance to KRAS inhibitors [65].”
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Hippo signaling pathway, a kinase cascade that regulates many physiological processes such as organ size determination, cell proliferation, and tissue regeneration, has been shown to play a key role in resistance to KRAS inhibition [102].”
Gao, T., Wang, Z., Zhou, J., Wang, D., Hou, X., Lin, X., Wang, Z., Chang, J., Liu, J., & Ren, C. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155437 · Cited by 6
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Dekker, S. E., & Deng, L. (2024) · Cancers · doi:10.3390/cancers16223885 · Cited by 7
“Recent studies have demonstrated that Hippo (YAP/TAZ) signaling is a significant contributor to resistance against KRAS G12C inhibitors in vitro and in vivo [38,39].”
Metadata
- Authors
- Mira, A., & Ambrogio, C.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Ambrogio, Chiara
- Venue
- Nature Cancer
- Published
- 2023-06-27
- Volume
- 4
- Issue
- 6
- Pages
- 784-786
- ISSN
- 2662-1347 (ISSN-L)
- OpenAlex
- W4382240796
- Cited by
- 10
- References
- 15
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- YAP, TAZ, KRAS inhibitors, adaptive drug resistance, mutant KRAS, Hippo signaling pathway, therapeutic target
- MeSH terms
- Transcription Factors, Proto-Oncogene Proteins p21(ras), Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors. https://app.cochat.ai/papers/10.1038/s43018-023-00580-5
- The paper
- Mira, A., & Ambrogio, C. (2023). YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors. Nature Cancer. https://doi.org/10.1038/s43018-023-00580-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.